0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      ACTH and Brain RNA: Changes in Content and Labelling of RNA in Rat Brain Stem

      ,

      Neuroendocrinology

      S. Karger AG

      ACTH, Adrenalectomy, Corticosteroids, Brain RNA

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The influence of synthetic ACTH<sub>1-24</sub> and acth <sub>1-24</sub> on rat brain RNA was studied. ACTH<sub>1-24</sub> (5 IU/100 g s.c.) treatment resulted in a small decrease in labelling of brain stem RNA (-12%), measured 30 min after the injection of [5-<sup>3</sup>H] uridine (100 µCi; s.c), without affecting the distribution of radioactivity of the acid-soluble precursor pool. Furthermore, a small and transitional reduction of total brain stem RNA was found. Similar treatment of adrenalectomized rats (36 h after surgery) resulted in a marked increase (+ 40%) in labelling of brain stem RNA, without affecting the distribution of radioactivity in the acid-soluble pool. In both intact and adrenalectomized rats, treatment with ACTH<sub>1-24</sub> did not affect RNA of cortex cerebrum and cerebellum. ACTH<sub>1-10</sub>, a fragment of ACTH without corticotropic activity in vivo, exhibited no effect on brain stem RNA in either intact or adrenalectomized rats, nor did corticosterone (1 mg/100 g) affect adrenalectomized rats.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1976
          1976
          25 March 2008
          : 21
          : 2
          : 97-110
          Affiliations
          Division of Molecular Neurobiology, Rudolf Magnus Institute for Pharmacology, and Laboratory of Physiological Chemistry, Medical Faculty, Institute of Molecular Biology, University of Utrecht, Utrecht
          Article
          122516 Neuroendocrinology 1976;21:97–110
          10.1159/000122516
          189247
          © 1976 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 14
          Categories
          Paper

          Comments

          Comment on this article